- Home
- PLXS vs TMDX Comparison
PLXS vs TMDX Comparison
Compare PLXS & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLXS
- TMDX
- Stock Information
- Founded
- PLXS 1979
- TMDX 1998
- Country
- PLXS United States
- TMDX United States
- Employees
- PLXS N/A
- TMDX N/A
- Industry
- PLXS Electrical Products
- TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- PLXS Technology
- TMDX Health Care
- Exchange
- PLXS Nasdaq
- TMDX Nasdaq
- Market Cap
- PLXS 3.8B
- TMDX 3.9B
- IPO Year
- PLXS 1986
- TMDX 2019
- Fundamental
- Price
- PLXS $140.36
- TMDX $114.30
- Analyst Decision
- PLXS Buy
- TMDX Buy
- Analyst Count
- PLXS 4
- TMDX 11
- Target Price
- PLXS $157.50
- TMDX $130.73
- AVG Volume (30 Days)
- PLXS 172.4K
- TMDX 1.0M
- Earning Date
- PLXS 10-22-2025
- TMDX 10-29-2025
- Dividend Yield
- PLXS N/A
- TMDX N/A
- EPS Growth
- PLXS 56.11
- TMDX 170.70
- EPS
- PLXS 6.26
- TMDX 2.54
- Revenue
- PLXS $4,032,966,000.00
- TMDX $566,354,000.00
- Revenue This Year
- PLXS $10.81
- TMDX $38.84
- Revenue Next Year
- PLXS $7.18
- TMDX $20.46
- P/E Ratio
- PLXS $22.42
- TMDX $45.35
- Revenue Growth
- PLXS 1.82
- TMDX 41.20
- 52 Week Low
- PLXS $103.43
- TMDX $55.00
- 52 Week High
- PLXS $172.89
- TMDX $145.50
- Technical
- Relative Strength Index (RSI)
- PLXS 45.79
- TMDX 40.85
- Support Level
- PLXS $142.40
- TMDX $115.21
- Resistance Level
- PLXS $147.57
- TMDX $125.57
- Average True Range (ATR)
- PLXS 4.67
- TMDX 7.65
- MACD
- PLXS -0.41
- TMDX -1.72
- Stochastic Oscillator
- PLXS 43.68
- TMDX 12.41
About PLXS Plexus Corp.
Plexus Corp is a U.S based Electronic Manufacturing Services company that provides a range of services, from conceptualization and design to fulfilling orders and providing sustaining solutions, such as replenishment and refurbishment. The company's segments comprise AMER, APAC,ge and EMEA.
About TMDX TransMedics Group Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.